Protara Therapeutics Q3 2026 net loss widens 64% to $21.69 million

Bitget2026/11/06 13:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Protara Therapeutics’ third-quarter 2026 net loss widened 64% year over year to $21.69 million.
Research and development expenses jumped 75% year over year to $16.81 million.
Cash, cash equivalents and marketable debt securities totaled $143.1 million at September 30, expected to fund planned operations into 2028.
Enrollment should finish for ADVANCED-2’s BCG-Unresponsive cohort by year-end 2026 and STARBORN-1 early in the first quarter of 2027.
A November 4 agreement covers $8.75 million of TARA-002 manufacturing-related assets from Novex Innovations to bring manufacturing in-house.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060800PRIMZONEFULLFEED9872020) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Protara Therapeutics Q3 2026 net loss widens 64% to $21.69 million

You may also like

Crypto prices